Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study

Joan L. Walker, Mark F. Brady, Lari Wenzel, Gini F. Fleming, Helen Q. Huang, Paul A. Disilvestro, Keiichi Fujiwara, David S. Alberts, Wenxin Zheng, Krishnansu S. Tewari, David E. Cohn, Matthew A. Powell, Linda Van Le, Susan A. Davidson, Heidi J. Gray, Peter G. Rose, Carol Aghajanian, Tashanna Myers, Angeles Alvarez Secord, Stephen C. RubinRobert S. Mannel

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)474-476
Number of pages3
JournalObstetrical and Gynecological Survey
Volume74
Issue number8
DOIs
StatePublished - Aug 1 2019

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., Disilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., Cohn, D. E., Powell, M. A., Van Le, L., Davidson, S. A., Gray, H. J., Rose, P. G., Aghajanian, C., Myers, T., Secord, A. A., ... Mannel, R. S. (2019). Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study. Obstetrical and Gynecological Survey, 74(8), 474-476. https://doi.org/10.1097/01.ogx.0000576976.42254.c2